The cost of GLP-1 medications to group health plans continues to increase rapidly as FDA approval expands and the percentage of participants and beneficiaries taking GLP-1 medications rises. This ...
In a data-driven world, pauses in government economic reporting do more than inconvenient economists, they create dangerous blind spots for investors, policymakers, and business leaders. When ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results